I suppose one counter-argument might be that if the data is public, drug companies would have more transparency into the FDAs methods, that might allow them to tailor their trials in a way to target the FDA's criteria in a way that would be bad for outcomes? Maybe?
But I come down on the same side, more transparency is probably better, and the FDA really probably only resists transparency here to avoid their own accountability to the public.